DAAs drive down liver transplant rate: First study
Universal access to the antivirals appears to have turned the tide of hepatis C-related transplantation, gastroenterologists say
Government subsidy of direct-acting antivirals for hepatitis C is driving down the rate of liver transplants and deaths from the disease, a registry study suggests.
The previous steady climb in adult transplantation – at a mean rate of 3.5 a year – has been stymied, with 7.9 fewer transplants per annum since PBS listing of the drugs in 2016, researchers say.
